Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab added to temozolomide-based therapy for pediatric high-grade glioma
NL-OMON39454Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in glioma and brain neoplasm (3 arms), sponsored by Roche. Primary endpoint: Event-free survival. Started Dec 2011; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
gliomabrain neoplasm
Beyond the preview
Go deeper on NL-OMON39454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39454.